Clinical Trials Directory

Trials / Unknown

UnknownNCT03367143

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

A Phase II Study of the Efficacy and Safety of Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed Diffuse Large B-cell Lymphoma

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
39 (estimated)
Sponsor
Ruijin Hospital · Academic / Other
Sex
All
Age
16 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.

Conditions

Interventions

TypeNameDescription
DRUGLenalidomide
DRUGIfosfamide
DRUGCarboplatin
DRUGEtoposide

Timeline

Start date
2016-12-01
Primary completion
2020-12-01
Completion
2020-12-01
First posted
2017-12-08
Last updated
2020-03-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03367143. Inclusion in this directory is not an endorsement.

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL (NCT03367143) · Clinical Trials Directory